Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Original reporting
Read the source story
Current understanding
Current understanding
No independent AtlasWire summary is available yet.
Impact assessment
Assessment in progress
This report is waiting for its impact assessment. AtlasWire does not treat missing evidence as low impact.
Reliability is still being assessed.